Pages that link to "Q31143293"
Jump to navigation
Jump to search
The following pages link to A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. (Q31143293):
Displaying 43 items.
- Crystal structure of a 3B3 variantâ A broadly neutralizing HIV-1 scFv antibody (Q27657585) (← links)
- Structure of an unliganded simian immunodeficiency virus gp120 core (Q29616089) (← links)
- The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1. (Q30441682) (← links)
- Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120 (Q30524225) (← links)
- Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. (Q30843874) (← links)
- A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. (Q31132248) (← links)
- Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. (Q33269999) (← links)
- An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 (Q33272711) (← links)
- Libraries against libraries for combinatorial selection of replicating antigen-antibody pairs (Q33399397) (← links)
- R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models (Q33640144) (← links)
- Comparing antigenicity and immunogenicity of engineered gp120. (Q33984309) (← links)
- Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody (Q33990484) (← links)
- Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. (Q34045535) (← links)
- Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study (Q34057606) (← links)
- Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine (Q34225659) (← links)
- Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques (Q34301728) (← links)
- The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection (Q34317025) (← links)
- Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody (Q34353296) (← links)
- Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis. (Q34432690) (← links)
- Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization (Q34441935) (← links)
- Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins (Q34637968) (← links)
- Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo (Q35024202) (← links)
- IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis (Q35556713) (← links)
- Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection (Q35635163) (← links)
- Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes (Q35745442) (← links)
- Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy (Q35785338) (← links)
- Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor (Q36509765) (← links)
- Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. (Q37072702) (← links)
- Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope (Q37092741) (← links)
- Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment (Q37410770) (← links)
- Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies (Q37583414) (← links)
- Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope (Q37596817) (← links)
- Structural Analysis of the Glycosylated Intact HIV-1 gp120-b12 Antibody Complex Using Hydroxyl Radical Protein Footprinting (Q37656791) (← links)
- A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation (Q37683178) (← links)
- Antibody-antigen pair probed by combinatorial approach and rational design: bringing together structural insights, directed evolution, and novel functionality (Q38030235) (← links)
- Glycosylation site-specific analysis of clade C HIV-1 envelope proteins (Q39824069) (← links)
- Rapid, quantitative mapping of anti-HIV type 1 envelope serum antibody specificities (Q40682905) (← links)
- Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. (Q40721814) (← links)
- Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. (Q45417687) (← links)
- Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity (Q45421316) (← links)
- Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. (Q46148243) (← links)
- Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV-1 (Q61962329) (← links)
- Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response (Q81367931) (← links)